ONI Competitive Intelligence & Landscape

ONI's primary product is the desktop Nanoimager microscopy platform, which democratizes the ability to perform advanced imaging. Complementing this, they offer products like Aplo Scope and Aplo Flow, alongside CODI Kits. Their services include EV Sample Characterization and LNP Sample Characterization, catering to nanoparticle applications. The company leverages various advanced imaging technologies such as dSTORM, PALM, DNA-PAINT, Single Particle Tracking (SPT), smFRET, Epifluorescence, HILO, and TIRF [oni.bio/]. These offerings serve a broad market, including researchers in cell biology, immuno-oncology, neuroscience, epigenetic mapping, cell phenotyping, and microbiology (including virology).

Headquartered in both San Diego, CA, and Oxford, UK, ONI was established with the goal of making super-resolution microscopy more accessible [oni.bio/news/oni-closes-75-million-dollar-series-b/]. The company received significant backing, closing a $75 million Series B financing round in January 2022, led by ARCH Venture Partners and Casdin Capital, among others [oni.bio/news/oni-closes-75-million-dollar-series-b/]. Paul Scagnetti was appointed CEO in February 2023, succeeding the founding CEO, to accelerate commercial growth and expand ONI's impact in research and discovery [oni.bio/leadership/], [oni.bio/news/news-oni-appoints-new-ceo-paul-scagnetti/].

ONI is committed to fostering a workplace that values diversity and inclusion, believing that unique perspectives and talents contribute to collective success across all aspects of employment [oni.bio/careers/]. They provide extensive learning resources, including user guides, publications, and trainings, to support users at every stage of their super-resolution journey, from beginners to those planning complex experiments [oni.bio/].

ONI's software and kits are integral to their offerings. The CODI Kits include CODI software, a cloud-based solution for automated image acquisition, analysis, and reporting, featuring unlimited storage and customizable analysis workflows [https://oni.bio/nanoimager/software/codi-software/]. For specific applications, ONI provides specialized reagent kits such as the LNP Profiler Kit with AutoLNP for characterizing Lipid Nanoparticles (LNPs) [https://oni.bio/kits/] and EV Profiler 2 for advanced extracellular vesicle visualization and phenotyping [https://oni.bio/evprofiler2/]. The EV Profiler 2 is highly configurable, allowing users to select options tailored to their research needs [https://oni.bio/ev-profiler-2-product-selection-tool/].

In addition to product sales, ONI offers expert services for sample characterization, utilizing their in-house equipment and kits. This includes LNP Sample Characterization, where ONI's team uses the Aplo Scope and LNP Profiler Kit with AutoLNP to provide insights into LNP formulations with single-molecule sensitivity [https://oni.bio/lnp-sample-characterization/]. Similarly, their EV Sample Characterization service employs the Nanoimager and EV Profiler kit to analyze extracellular vesicle samples [https://oni.bio/ev-sample-characterization/]. These services provide a streamlined, end-to-end solution from sample preparation to high-resolution data delivery. While direct pricing isn't listed, the emphasis on comprehensive solutions and expert support suggests a value-driven approach for researchers seeking advanced microscopy capabilities.

Recent job postings reveal a consistent demand for specialized skills.

ONI is actively recruiting for roles such as Senior Software Engineer, C++, Image Processing, ML [https://oni.bio/lever-job/senior-software-engineer-c-image-processing-ml/], Senior Systems Integration Engineer [https://oni.bio/lever-job/senior-systems-integration-engineer/], and Field Application Scientists [https://oni.bio/lever-job/field-application-scientist-12-month-maternity-cover/]. These openings, spanning locations like Oxford (UK), San Francisco, CA (Remote), San Diego, CA (On-site), and Boston, MA (Remote) [https://oni.bio/careers/], highlight a strategic investment in both its research and development capabilities and its customer-facing operations. The presence of remote and hybrid roles also suggests flexibility in attracting top talent.

The diverse nature of ONI's job openings, including a Sales Executive role [https://oni.bio/lever-job/sales-executive/], underscores a deliberate strategy to not only innovate within super-resolution microscopy but also to aggressively market and support its products like the Nanoimager. While specific layoff information is not available, the consistent pattern of open positions across engineering, scientific, and commercial departments indicates a period of growth and expansion rather than contraction. This sustained hiring trend aligns with a company focused on strengthening its technological foundation and extending its influence within the scientific community.

While specific revenue figures are not publicly disclosed, the substantial Series B funding indicates a healthy financial position and provides ONI with considerable capital to fuel its expansion, research and development, and market penetration. The company's Nanoimager has already been adopted by over 100 customers worldwide since its founding in 2016 as an Oxford University spin-out, suggesting a strong market demand for its desktop-sized, single-molecule microscopy solution [https://oni.bio/news/patrick-finn-joins-bod/]. This widespread adoption points to solid sales and a growing customer base.

ONI's financial health is further supported by its robust leadership team, including Brenton Keath as Chief Financial Officer, indicating a focus on strategic financial management [https://oni.bio/leadership/]. The company also actively provides grants and research funding assistance to its users, demonstrating a commitment to fostering scientific discovery and potentially expanding its market reach by enabling more researchers to access its cutting-edge technology [https://oni.bio/grants/]. Although no mergers or acquisitions by ONI are detailed in the provided information, the significant Series B funding positions the company for potential strategic growth initiatives in the future.

Upcoming in-person events for ONI include key conferences such as JCS2026: Imaging Cell Dynamics, held in Catalonia, Spain, from May 11-14, 2026, and Synergy for Science 2026 in Glasgow, UK, from July 12-16, 2026 [oni.bio/events/].

ONI also attends specialized summits like the CRBE Summit West, which took place in San Diego, California, from February 24-25, 2026 [oni.bio/event/crbe-summit-west/]. These conferences allow ONI to connect directly with researchers, share insights, and present the latest applications of their super-resolution microscopy platforms.

In addition to physical events, ONI hosts a series of virtual trainings and webinars under the banner “Live from the Lab,” designed to provide in-depth technical guidance and practical demonstrations. These include sessions on specific imaging techniques and applications, such as “dSTORM Imaging” on June 25, 2026, “LNP Imaging” on July 23, 2026, and “EV Imaging” on August 20, 2026 [oni.bio/livefromthelab/]. Other virtual events have covered topics like “Small dyes, big impact: Enabling gentle super-resolution imaging in live cells” on March 31, 2026 [oni.bio/event/enabling-gentle-super-resolution-imaging-in-live-cells/] and “Automated DNA-PAINT and Exchange Imaging with Aplo Flow Fluidics” on March 3, 2026 [oni.bio/event/webinar-automated-dna-paint-and-exchange-imaging-with-aplo-flow-fluidics2/]. These online offerings are crucial for making advanced microscopy techniques accessible to a wider audience, facilitating continuous learning and skill development in the field.